Roche Holding AG (RHHBY)
| Market Cap | 280.65B |
| Revenue (ttm) | 79.83B |
| Net Income (ttm) | 11.86B |
| Shares Out | n/a |
| EPS (ttm) | 14.77 |
| PE Ratio | 23.67 |
| Forward PE | 13.75 |
| Dividend | 0.87 (2.13%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 169,895 |
| Average Volume | 1,790,611 |
| Open | 41.05 |
| Previous Close | 40.85 |
| Day's Range | 40.32 - 41.05 |
| 52-Week Range | 34.10 - 45.94 |
| Beta | 0.18 |
| RSI | 31.57 |
| Earnings Date | Oct 27, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial numbers in CHF Financial StatementsNews
Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue
Basel, 29 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE mark for its Elecsys® Dengue Ag test – a high-throughput, fully automated immunoassay to be used as ...
Positive Phase III Results for Genentech's Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the P...
Roche Holding AG (RHHBY) Q3 2025 Sales Call Transcript
Roche Holding AG (OTCQX:RHHBY) Q3 2025 Sales Call October 23, 2025 8:00 AM EDTCompany ParticipantsThomas Schinecker - Group Chief Executive OfficerAlan...
Roche Raises Full-Year Earnings Outlook
The pharma group lifted its guidance citing strong results to date, and reported a rise in sales excluding currency movements.
Changes to the Roche Enlarged Corporate Executive Committee
Basel, 23 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Nina Schwab-Hautzinger (1975) has been appointed Head of Group Communications and a member of the enlarged Corporate Ex...
Roche raises guidance on forecast-beating nine-month sales
Swiss drugmaker Roche on Thursday lifted its full-year guidance after reporting nine-month sales that were better than expected.
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Holding AG (RHHBY) Shareholder/Analyst Call - Slideshow
Top 3 Health Care Stocks You'll Regret Missing In October
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go ...
FDA Approves Roche's Gazyva for Lupus Nephritis
FDA Approves Roche's Gazyva for Lupus Nephritis
My Top 3 Pharma Stocks
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o...
Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche
Rapt stock surged Monday after the biotech company said its experimental hives treatment topped Roche's Xolair in a 16-week study.
'Why the world is falling to bits?': Roche on his upcoming book
David Roche, president of Quantum Strategy discusses his new book, "Consequences: The Rise of a Fractured World Order" which talks about the global state of democracy and what entities are profiting o...
Roche's Gazyva Gets FDA Approval for Lupus Nephritis
The Food and Drug Administration approved Gazyva for the treatment of adults receiving standard therapy for a form of lupus that targets the kidneys.
Roche: FDA Approves Gazyva/Gazyvaro In Treatment Of Lupus Nephritis
(RTTNews) - Roche (RHHBY.PK) announced the FDA has approved Gazyva/Gazyvaro for the treatment of adult patients with active lupus nephritis who are receiving standard therapy, as well as a shorter 90-...
Roche's Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for peopl...
Genentech's Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III IMvigor011 study evaluating Tecen...
FDA approves Roche's Gazyva/Gazyvaro for the treatment of lupus nephritis
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro®(obinutuzumab) for the treatment of adult patie...
FDA Approves Genentech's Gazyva for the Treatment of Lupus Nephritis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva®...
Roche's Vamikibart Shows Promising Efficacy In Uveitic Macular Edema Across Phase III Trials
(RTTNews) - Roche has announced encouraging results from two Phase III clinical trials evaluating the investigational drug vamikibart (0.25 mg and 1 mg doses) for the treatment of uveitic macular edem...
Roche breast cancer drug improves survival of up to 62% in late-stage trial
Roche (RHHBF) unit Genentech posts encouraging late-stage trial data for its breast cancer drug giredestrant noting up to 62% survival benefit. Read more here.
Genentech's Giredestrant Combo Shows Strong Phase III Results In Advanced Breast Cancer Trial
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced positive results from the Phase III evERA Breast Cancer study. The data revealed that giredestrant in combination with everolimus ...
Genentech's Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA Breast Cancer study. Data s...
Roche's phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
Basel, 18 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus signi...
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Basel, 17 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from two phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 and 1...